Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...

Discover key insights from Pharming Group's Q4 2024 earnings call. Explore strong revenue growth, RUCONEST & Joenja drivers, and 2025 strategic priorities.

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Good day and thank you for standing by. Welcome to the Pharming Group Fourth Quarter and Full-year 2024 Results Conference Call and Webcast. [Operator Instructions] Please be advised that today's ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...

The European market has recently experienced a slight downturn, with the pan-European STOXX Europe 600 Index ending lower amid ongoing uncertainty about U.S. trade policy. Despite these challenges, ...

(RTTNews) - Pharming Group N.V. (PHAR), a global biopharmaceutical company, on Thursday reported profit for the fourth quarter compared with loss last year. In the fourth quarter, net income came ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming's late-stage clinical pipeline, in line with our vision to become a leading global rare disease company Fabrice ...

Chief Executive Officer, Fabrice Chouraqui commented: "I am delighted to have been appointed as CEO of Pharming and am deeply excited for the opportunities that lie ahead. The strength of the ...